Table 2.
New-onset diabetes mellitus (NODM) between rosuvastatin and atorvastatin treatment
| Rosuvastatin | Atorvastatin | HR (95% CI) | P-value | |
|---|---|---|---|---|
| Intention-to-treat population | 152/1479 (10.4) | 119/1453 (8.4) | 1.26 (0.99 to 1.60) | 0.058 |
| As-treated population* | ||||
| Overall patients | 127/1259 (10.2) | 91/1118 (8.3) | 1.24 (0.95 to 1.63) | 0.115 |
| Low to moderate-intensity statin | 21/290 (6.9) | 18/244 (7.0) | 0.98 (0.52 to 1.84) | 0.948 |
| High-intensity statin | 106/948 (11.4) | 73/856 (8.8) | 1.32 (0.98 to 1.77) | 0.071 |
| Achieved LDL-C levels† | ||||
| < 70 mg/dL | 71/517 (13.9) | 31/398 (8.0) | 1.79 (1.18 to 2.73) | 0.007 |
| ≥ 70 mg/dL | 35/431 (8.3) | 42/458 (9.4) | 0.87 (0.56 to 1.37) | 0.549 |
Data are number of patients/total number of patients (%). CI = confidence interval; HR = hazard ratio; LDL-C = low-density lipoprotein cholesterol
* As-treated population was defined according to the actually received type of the statin after exclusion of those who received ezetimibe or a statin other than rosuvastatin or atorvastatin
† From the cubic spline analysis plotting, an increase of NODM in the rosuvastatin group versus the atorvastatin group began below an achieved LDL-C level of 70 mg/dL, which was determined as a cut-off value. An interaction test was performed between the type of statin (rosuvastatin versus atorvastatin) and the achieved LDL-C levels (< 70 versus ≥ 70 mg/dL). The P value for interaction was 0.022